Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
1.57 (1y: +41%)
Market Cap 11.82 M P/E(ttm)
Enterprise Value 20.24 M P/B 1.46
BASI- NAS (USA)
Bioanalytical Systems, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star (On Watch)
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$1.57
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry		 vs
history
Cash to Debt 0.086
BASI's Cash to Debt is ranked lower than
93% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.36 vs. BASI: 0.086 )
BASI' s 10-Year Cash to Debt Range
Min: 0.03   Max: 0.31
Current: 0.09
0.03
0.31
Equity to Asset 0.304
BASI's Equity to Asset is ranked lower than
89% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. BASI: 0.304 )
BASI' s 10-Year Equity to Asset Range
Min: 0.3   Max: 0.6
Current: 0.3
0.3
0.6
F-Score: 3
Z-Score: -0.1
M-Score: -3.56
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry		 vs
history
Operating margin (%) -20.20
BASI's Operating margin (%) is ranked lower than
1694914% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.50 vs. BASI: -20.20 )
BASI' s 10-Year Operating margin (%) Range
Min: -20.2   Max: 13.8
Current: -20.2
-20.2
13.8
Net-margin (%) -22.7
BASI's Net-margin (%) is ranked lower than
1754384% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.60 vs. BASI: -22.7 )
BASI' s 10-Year Net-margin (%) Range
Min: -22.7   Max: 7
Current: -22.7
-22.7
7
ROE (%) -66.6
BASI's ROE (%) is ranked lower than
1785713% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.30 vs. BASI: -66.6 )
BASI' s 10-Year ROE (%) Range
Min: -66.6   Max: 9.9
Current: -66.6
-66.6
9.9
ROA (%) -23.7
BASI's ROA (%) is ranked lower than
1754384% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.40 vs. BASI: -23.7 )
BASI' s 10-Year ROA (%) Range
Min: -23.7   Max: 6.3
Current: -23.7
-23.7
6.3
ROC (Joel Greenblatt) (%) -36.10
BASI's ROC (Joel Greenblatt) (%) is ranked lower than
1694914% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.80 vs. BASI: -36.10 )
BASI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -36.1   Max: 16
Current: -36.1
-36.1
16
Revenue Growth (%) -11.7
BASI's Revenue Growth (%) is ranked lower than
2173911% of the 46 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.60 vs. BASI: -11.7 )
BASI' s 10-Year Revenue Growth (%) Range
Min: -11.7   Max: 11
Current: -11.7
-11.7
11
EBITDA Growth (%) 4.7
BASI's EBITDA Growth (%) is ranked lower than
79% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.80 vs. BASI: 4.7 )
BASI' s 10-Year EBITDA Growth (%) Range
Min: -50.6   Max: 65.5
Current: 4.7
-50.6
65.5
EPS Growth (%) -5.4
BASI's EPS Growth (%) is ranked lower than
5882347% of the 17 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.10 vs. BASI: -5.4 )
BASI' s 10-Year EPS Growth (%) Range
Min: -5.4   Max: 96.8
Current: -5.4
-5.4
96.8
ยป BASI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

BASI Guru Trades in Q2 2012

Jim Simons 27,100 sh (-4.91%)
» More
Q3 2012

BASI Guru Trades in Q3 2012

Jim Simons 25,800 sh (-4.8%)
» More
Q4 2012

BASI Guru Trades in Q4 2012

Jim Simons 25,500 sh (-1.16%)
» More
Q1 2013

BASI Guru Trades in Q1 2013

Jim Simons 26,900 sh (+5.49%)
» More
» Details

Insider Trades

Latest Guru Trades with BASI



No Insider Trades Found!

Ratios

vs
industry		 vs
history
P/B 1.46
BASI's P/B is ranked higher than
83% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.64 vs. BASI: 1.46 )
BASI' s 10-Year P/B Range
Min: 0.23   Max: 3.62
Current: 1.46
0.23
3.62
P/S 0.67
BASI's P/S is ranked higher than
92% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.43 vs. BASI: 0.67 )
BASI' s 10-Year P/S Range
Min: 0.1   Max: 2.62
Current: 0.67
0.1
2.62
PFCF 31.40
BASI's PFCF is ranked higher than
53% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.60 vs. BASI: 31.40 )
BASI' s 10-Year PFCF Range
Min: 1.61   Max: 375
Current: 31.4
1.61
375
EV-to-EBIT -81.94
BASI's EV-to-EBIT is ranked lower than
299% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.90 vs. BASI: -81.94 )
BASI' s 10-Year EV-to-EBIT Range
Min: 8.2   Max: 189.7
Current: -81.94
8.2
189.7
Shiller P/E 307.7
BASI's Shiller P/E is ranked lower than
100% of the Companies
in the Global Diagnostics & Research industry.

( Industry Median: vs. BASI: 307.7 )
BASI' s 10-Year Shiller P/E Range
Min: 42.22   Max: 774
Current: 307.7
42.22
774

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 7
BASI's Price/Net Current Asset Value is ranked higher than
71% of the 87 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.80 vs. BASI: 7 )
BASI' s 10-Year Price/Net Current Asset Value Range
Min: 2.8   Max: 45.8
Current: 7
2.8
45.8
Price/Tangible Book 1.8
BASI's Price/Tangible Book is ranked higher than
89% of the 88 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. BASI: 1.8 )
BASI' s 10-Year Price/Tangible Book Range
Min: 0.4   Max: 2.1
Current: 1.8
0.4
2.1
Price/DCF (Projected) 0.9
BASI's Price/DCF (Projected) is ranked higher than
86% of the 37 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. BASI: 0.9 )
BASI' s 10-Year Price/DCF (Projected) Range
Min: 0.3   Max: 12.8
Current: 0.9
0.3
12.8
Price/Median PS Value 0.8
BASI's Price/Median PS Value is ranked higher than
75% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. BASI: 0.8 )
BASI' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 1.9
Current: 0.8
0.3
1.9
Earnings Yield (Greenblatt) 7.80
BASI's Earnings Yield (Greenblatt) is ranked lower than
1388888% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.60 vs. BASI: 7.80 )
BASI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 12.1
Current: 7.8
0.5
12.1
Forward Rate of Return (Yacktman) 8.6
BASI's Forward Rate of Return (Yacktman) is ranked lower than
64% of the 33 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.26 vs. BASI: 8.6 )
BASI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -17.9   Max: 29.6
Current: 8.6
-17.9
29.6

Business Description

Bioanalytical Systems, Inc., was incorporated in the State of Indiana. The Company is an international contract research organization providing drug discovery and development services. Its clients and partners include pharmaceutical, biotechnology, academic and government organizations. It offers an efficient, variable-cost alternative to its clients' internal product development programs. Outsourcing development work to reduce overhead and speed drug approvals through the Food and Drug Administration (FDA) is an established alternative to in-house development among pharmaceutical companies. It derives its revenues from sales of its research services and drug development tools, both of which are focused on determining drug safety and efficacy. The Company supports the preclinical and clinical development needs of researchers and clinicians for small molecule and large biomolecule drug candidates. Its scientists have the skills in analytical instrumentation development, chemistry, computer software development, physiology, medicine, analytical chemistry and toxicology to make the services and products it provides increasingly valuable to its current and potential clients. The Company's main clients are scientists engaged in analytical chemistry, drug safety evaluation, clinical trials, drug metabolism studies, pharmacokinetics and basic neuroscience research from small start-up biotechnology companies to many of the largest global pharmaceutical companies. Its services and products are marketed globally to pharmaceutical, medical research and biotech companies and institutions engaged in drug research and development. The research services industry is highly fragmented among many niche vendors led by a small number of larger companies; the latter offer an ever-growing portfolio of start-to-finish pharmaceutical development services. It competes with in-house research, development, quality control and other support service departments of pharmaceutical and biotechnology companies. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products.
Company Website
SEC Reports
Industry: Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ
Traded in other countries:BS5.Germany
ยป More Articles for BASI

Headlines

Articles On GuruFocus.com
Bioanalytical Systems Inc. Reports Operating Results (10-Q) Feb 09 2011 
Bioanalytical Systems Inc. Reports Operating Results (10-Q/A) May 20 2010 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) May 17 2010 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) Feb 16 2010 
Bioanalytical Systems Inc. Reports Operating Results (10-K/A) Feb 10 2010 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) Aug 12 2009 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) May 18 2009 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) Feb 23 2009 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial